

1648

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

William Fields
Type or print name

William Fields
Signature

July 14, 2003
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

HALLENBECK ET AL.

APPLICATION NO: 09/870,203

FILED: MAY 30, 2001

FOR: ADENOVIRUS PARTICLES WITH MUTAGENIZED FIBER
PROTEINS

Examiner: Myron Hill

Art Unit: 1648

Confirmation No.: 7861

Atty. Docket: 4-31452A

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
JUL 17 2003
TECH CENTER 1600/2900

TRANSMITTAL LETTER

Sir:

Enclosed please find the following:

- a. Supplemental Information Disclosure Statement;
- b. PTO Form 1449 with cited references; and
- c. Return postcard.

Respectfully submitted,

J. Timothy Meigs

J. Timothy Meigs
Attorney for Applicants
Reg. No. 38,241

Novartis
Corporate Intellectual Property
One Health Plaza, Bldg. 430
East Hanover, NJ 07936-1080
Phone No. (301) 208-2440

Date: July 14, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JUL 17 2003
TECH CENTER 1600/2900

IN RE APPLICATION OF

Art Unit: 1648

HALLENBECK ET AL.

Examiner: Myron Hill

APPLICATION NO: 09/870,203

FILED: MAY 30, 2001

FOR: ADENOVIRUS PARTICLES WITH MUTAGENIZED FIBER
PROTEINS

Commissioner for Patents
U.S. Patent and Trademark Office
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is submitted in accordance with 37 CFR §1.97(c) and is supplemental to the Information Disclosure Statement filed December 14, 2001. Pursuant to 37 C.F.R. §1.97(e)(1), each item of information contained in this supplemental information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this supplemental information disclosure statement.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(301) 258-4715

Respectfully submitted,


J. Timothy Meigs
Attorney for Applicants
Reg. No. 38,241

Date: July 14, 2003

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

4-31452A

APPLICATION NO.


09/870,203

APPLICANT

HALLENBECK ET AL.

FILING DATE

MAY 30, 2001

Group
1648

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

RECEIVED
JUL 17 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	WO 00/15823	3/23/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 98/07865	2/26/98	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 98/50053	11/12/98	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	International Search Report for PCT/EP01/06286, dated July 1, 2003
	AS	
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.